Serveur d'exploration Posturo

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side effects in healthy volunteers.

Identifieur interne : 001423 ( Main/Exploration ); précédent : 001422; suivant : 001424

Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side effects in healthy volunteers.

Auteurs : S. Noachtar [Allemagne] ; B. Von Maydell ; L. Fuhry ; U. Büttner

Source :

RBID : pubmed:9696300

Descripteurs français

English descriptors

Abstract

This prospective study examined the effects of the new antiepileptic drug (AED) gabapentin (GBP) compared to the standard AED carbamazepine (CBZ) and placebo (PLA) on eye movements, posture and finger force control in 12 healthy volunteers who received single doses of 600 mg GBP and 400 mg CBZ in a placebo-controlled, double-blind, cross-over, randomized trial. CBZ and GBP reduced almost equally (8% vs. 10%) the mean peak saccade velocity as compared to PLA (P < 0.05). CBZ, but not GBP, significantly prolonged the duration of saccades as compared to placebo (14-24%) (P < 0.05). GBP produced a greater maximal increase of body sway than CBZ with eyes open (P < 0.01) and eyes closed (P < 0.001). CBZ and GBP did not significantly influence control of grip force. CBZ effects were better correlated with plasma levels. Subjective side effects were more pronounced with CBZ than GBP. Although CBZ and GBP cause similar CNS side effects, the effects on eye movements and body sway were different. CBZ predominantly affects saccadic eye movements, whereas GBP had more impact on posture control. Thus, electro-oculography seems to be more appropriate in the detection of CBZ-induced side effects and posturography appears to be more sensitive in the detection of side effects associated with GBP.

DOI: 10.1016/s0920-1211(98)00015-1
PubMed: 9696300


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side effects in healthy volunteers.</title>
<author>
<name sortKey="Noachtar, S" sort="Noachtar, S" uniqKey="Noachtar S" first="S" last="Noachtar">S. Noachtar</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Neurology, University of Munich, Germany. Noachtar@brain.nefo.med.uni-muenchen.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, University of Munich</wicri:regionArea>
<placeName>
<settlement type="city">Munich</settlement>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author>
<name sortKey="Von Maydell, B" sort="Von Maydell, B" uniqKey="Von Maydell B" first="B" last="Von Maydell">B. Von Maydell</name>
</author>
<author>
<name sortKey="Fuhry, L" sort="Fuhry, L" uniqKey="Fuhry L" first="L" last="Fuhry">L. Fuhry</name>
</author>
<author>
<name sortKey="Buttner, U" sort="Buttner, U" uniqKey="Buttner U" first="U" last="Büttner">U. Büttner</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9696300</idno>
<idno type="pmid">9696300</idno>
<idno type="doi">10.1016/s0920-1211(98)00015-1</idno>
<idno type="wicri:Area/Main/Corpus">001423</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001423</idno>
<idno type="wicri:Area/Main/Curation">001423</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001423</idno>
<idno type="wicri:Area/Main/Exploration">001423</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side effects in healthy volunteers.</title>
<author>
<name sortKey="Noachtar, S" sort="Noachtar, S" uniqKey="Noachtar S" first="S" last="Noachtar">S. Noachtar</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Neurology, University of Munich, Germany. Noachtar@brain.nefo.med.uni-muenchen.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, University of Munich</wicri:regionArea>
<placeName>
<settlement type="city">Munich</settlement>
<region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
</placeName>
<orgName type="university">Université Louis-et-Maximilien de Munich</orgName>
</affiliation>
</author>
<author>
<name sortKey="Von Maydell, B" sort="Von Maydell, B" uniqKey="Von Maydell B" first="B" last="Von Maydell">B. Von Maydell</name>
</author>
<author>
<name sortKey="Fuhry, L" sort="Fuhry, L" uniqKey="Fuhry L" first="L" last="Fuhry">L. Fuhry</name>
</author>
<author>
<name sortKey="Buttner, U" sort="Buttner, U" uniqKey="Buttner U" first="U" last="Büttner">U. Büttner</name>
</author>
</analytic>
<series>
<title level="j">Epilepsy research</title>
<idno type="ISSN">0920-1211</idno>
<imprint>
<date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Acetates (administration & dosage)</term>
<term>Acetates (blood)</term>
<term>Acetates (pharmacology)</term>
<term>Administration, Oral (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Amines (MeSH)</term>
<term>Anticonvulsants (MeSH)</term>
<term>Carbamazepine (administration & dosage)</term>
<term>Carbamazepine (blood)</term>
<term>Carbamazepine (pharmacology)</term>
<term>Cross-Over Studies (MeSH)</term>
<term>Cyclohexanecarboxylic Acids (MeSH)</term>
<term>Double-Blind Method (MeSH)</term>
<term>Drug Administration Schedule (MeSH)</term>
<term>Electronystagmography (MeSH)</term>
<term>Electrooculography (MeSH)</term>
<term>Eye Movements (drug effects)</term>
<term>Female (MeSH)</term>
<term>Fingers (physiology)</term>
<term>Gabapentin (MeSH)</term>
<term>Hand Strength (physiology)</term>
<term>Humans (MeSH)</term>
<term>Isometric Contraction (drug effects)</term>
<term>Isometric Contraction (physiology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Placebos (MeSH)</term>
<term>Posture (physiology)</term>
<term>Prospective Studies (MeSH)</term>
<term>Saccades (drug effects)</term>
<term>Saccades (physiology)</term>
<term>Time Factors (MeSH)</term>
<term>gamma-Aminobutyric Acid (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Acide gamma-amino-butyrique (MeSH)</term>
<term>Acides cyclohexanecarboxyliques (MeSH)</term>
<term>Acétates (administration et posologie)</term>
<term>Acétates (pharmacologie)</term>
<term>Acétates (sang)</term>
<term>Administration par voie orale (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Amines (MeSH)</term>
<term>Anticonvulsivants (MeSH)</term>
<term>Calendrier d'administration des médicaments (MeSH)</term>
<term>Carbamazépine (administration et posologie)</term>
<term>Carbamazépine (pharmacologie)</term>
<term>Carbamazépine (sang)</term>
<term>Contraction isométrique (effets des médicaments et des substances chimiques)</term>
<term>Contraction isométrique (physiologie)</term>
<term>Doigts (physiologie)</term>
<term>Facteurs temps (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Force de la main (physiologie)</term>
<term>Gabapentine (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Mouvements oculaires (effets des médicaments et des substances chimiques)</term>
<term>Mâle (MeSH)</term>
<term>Méthode en double aveugle (MeSH)</term>
<term>Placebo (MeSH)</term>
<term>Posture (physiologie)</term>
<term>Saccades (effets des médicaments et des substances chimiques)</term>
<term>Saccades (physiologie)</term>
<term>Électro-oculographie (MeSH)</term>
<term>Électronystagmographie (MeSH)</term>
<term>Études croisées (MeSH)</term>
<term>Études prospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Acetates</term>
<term>Carbamazepine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Acetates</term>
<term>Carbamazepine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Acetates</term>
<term>Carbamazepine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Acétates</term>
<term>Carbamazépine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Eye Movements</term>
<term>Isometric Contraction</term>
<term>Saccades</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Contraction isométrique</term>
<term>Mouvements oculaires</term>
<term>Saccades</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Acétates</term>
<term>Carbamazépine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Contraction isométrique</term>
<term>Doigts</term>
<term>Force de la main</term>
<term>Posture</term>
<term>Saccades</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Fingers</term>
<term>Hand Strength</term>
<term>Isometric Contraction</term>
<term>Posture</term>
<term>Saccades</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Acétates</term>
<term>Carbamazépine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Administration, Oral</term>
<term>Adult</term>
<term>Amines</term>
<term>Anticonvulsants</term>
<term>Cross-Over Studies</term>
<term>Cyclohexanecarboxylic Acids</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Electronystagmography</term>
<term>Electrooculography</term>
<term>Female</term>
<term>Gabapentin</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Placebos</term>
<term>Prospective Studies</term>
<term>Time Factors</term>
<term>gamma-Aminobutyric Acid</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Acide gamma-amino-butyrique</term>
<term>Acides cyclohexanecarboxyliques</term>
<term>Administration par voie orale</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Amines</term>
<term>Anticonvulsivants</term>
<term>Calendrier d'administration des médicaments</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Gabapentine</term>
<term>Humains</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Placebo</term>
<term>Électro-oculographie</term>
<term>Électronystagmographie</term>
<term>Études croisées</term>
<term>Études prospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">This prospective study examined the effects of the new antiepileptic drug (AED) gabapentin (GBP) compared to the standard AED carbamazepine (CBZ) and placebo (PLA) on eye movements, posture and finger force control in 12 healthy volunteers who received single doses of 600 mg GBP and 400 mg CBZ in a placebo-controlled, double-blind, cross-over, randomized trial. CBZ and GBP reduced almost equally (8% vs. 10%) the mean peak saccade velocity as compared to PLA (P < 0.05). CBZ, but not GBP, significantly prolonged the duration of saccades as compared to placebo (14-24%) (P < 0.05). GBP produced a greater maximal increase of body sway than CBZ with eyes open (P < 0.01) and eyes closed (P < 0.001). CBZ and GBP did not significantly influence control of grip force. CBZ effects were better correlated with plasma levels. Subjective side effects were more pronounced with CBZ than GBP. Although CBZ and GBP cause similar CNS side effects, the effects on eye movements and body sway were different. CBZ predominantly affects saccadic eye movements, whereas GBP had more impact on posture control. Thus, electro-oculography seems to be more appropriate in the detection of CBZ-induced side effects and posturography appears to be more sensitive in the detection of side effects associated with GBP.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">9696300</PMID>
<DateCompleted>
<Year>1999</Year>
<Month>05</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>09</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0920-1211</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>31</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1998</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Epilepsy research</Title>
<ISOAbbreviation>Epilepsy Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side effects in healthy volunteers.</ArticleTitle>
<Pagination>
<MedlinePgn>47-57</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>This prospective study examined the effects of the new antiepileptic drug (AED) gabapentin (GBP) compared to the standard AED carbamazepine (CBZ) and placebo (PLA) on eye movements, posture and finger force control in 12 healthy volunteers who received single doses of 600 mg GBP and 400 mg CBZ in a placebo-controlled, double-blind, cross-over, randomized trial. CBZ and GBP reduced almost equally (8% vs. 10%) the mean peak saccade velocity as compared to PLA (P < 0.05). CBZ, but not GBP, significantly prolonged the duration of saccades as compared to placebo (14-24%) (P < 0.05). GBP produced a greater maximal increase of body sway than CBZ with eyes open (P < 0.01) and eyes closed (P < 0.001). CBZ and GBP did not significantly influence control of grip force. CBZ effects were better correlated with plasma levels. Subjective side effects were more pronounced with CBZ than GBP. Although CBZ and GBP cause similar CNS side effects, the effects on eye movements and body sway were different. CBZ predominantly affects saccadic eye movements, whereas GBP had more impact on posture control. Thus, electro-oculography seems to be more appropriate in the detection of CBZ-induced side effects and posturography appears to be more sensitive in the detection of side effects associated with GBP.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Noachtar</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, University of Munich, Germany. Noachtar@brain.nefo.med.uni-muenchen.de</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>von Maydell</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fuhry</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Büttner</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Epilepsy Res</MedlineTA>
<NlmUniqueID>8703089</NlmUniqueID>
<ISSNLinking>0920-1211</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000588">Amines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003509">Cyclohexanecarboxylic Acids</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33CM23913M</RegistryNumber>
<NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>56-12-2</RegistryNumber>
<NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6CW7F3G59X</RegistryNumber>
<NameOfSubstance UI="D000077206">Gabapentin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>S</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000588" MajorTopicYN="Y">Amines</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003509" MajorTopicYN="Y">Cyclohexanecarboxylic Acids</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004584" MajorTopicYN="N">Electronystagmography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004585" MajorTopicYN="N">Electrooculography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005133" MajorTopicYN="N">Eye Movements</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005385" MajorTopicYN="N">Fingers</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000077206" MajorTopicYN="N">Gabapentin</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007537" MajorTopicYN="N">Isometric Contraction</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011187" MajorTopicYN="N">Posture</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012438" MajorTopicYN="N">Saccades</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005680" MajorTopicYN="Y">gamma-Aminobutyric Acid</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>1998</Year>
<Month>8</Month>
<Day>8</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>1998</Year>
<Month>8</Month>
<Day>8</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>1998</Year>
<Month>8</Month>
<Day>8</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">9696300</ArticleId>
<ArticleId IdType="pii">S0920-1211(98)00015-1</ArticleId>
<ArticleId IdType="doi">10.1016/s0920-1211(98)00015-1</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Allemagne</li>
</country>
<region>
<li>Bavière</li>
<li>District de Haute-Bavière</li>
</region>
<settlement>
<li>Munich</li>
</settlement>
<orgName>
<li>Université Louis-et-Maximilien de Munich</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Buttner, U" sort="Buttner, U" uniqKey="Buttner U" first="U" last="Büttner">U. Büttner</name>
<name sortKey="Fuhry, L" sort="Fuhry, L" uniqKey="Fuhry L" first="L" last="Fuhry">L. Fuhry</name>
<name sortKey="Von Maydell, B" sort="Von Maydell, B" uniqKey="Von Maydell B" first="B" last="Von Maydell">B. Von Maydell</name>
</noCountry>
<country name="Allemagne">
<region name="Bavière">
<name sortKey="Noachtar, S" sort="Noachtar, S" uniqKey="Noachtar S" first="S" last="Noachtar">S. Noachtar</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PosturoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001423 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001423 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PosturoV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:9696300
   |texte=   Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side effects in healthy volunteers.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:9696300" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PosturoV1 

Wicri

This area was generated with Dilib version V0.6.37.
Data generation: Fri Nov 13 22:38:36 2020. Site generation: Thu Mar 25 16:16:50 2021